Original Articles

PTEN and PARP1 expression as predictors of neoadjuvant chemotherapy response in breast cancer: A case-control study

Ni Putu Sriwidyani , Herman Saputra

Ni Putu Sriwidyani
Department of Pathology Anatomy, Faculty of Medicine, Universitas Udayana/Sanglah General Hospital Denpasar-Bali. Email: sriwidyani@unud.ac.id

Herman Saputra
Department of Pathology Anatomy, Faculty of Medicine, Universitas Udayana/Sanglah General Hospital Denpasar-Bali
Online First: September 30, 2020 | Cite this Article
Sriwidyani, N., Saputra, H. 2020. PTEN and PARP1 expression as predictors of neoadjuvant chemotherapy response in breast cancer: A case-control study. Indonesia Journal of Biomedical Science 14(2): 78-81. DOI:10.15562/ijbs.v14i2.261


Background: Most breast cancer patients in developing countries present at an advanced stage and require neoadjuvant chemotherapy (NACT) before mastectomy. Chemotherapy in breast cancer generally kills cancer cells via apoptotic mechanisms, and chemotherapy response could be predicted by assessing biological markers associated with apoptosis, including phosphatase and tensin homolog deleted on chromosome ten (PTEN) and Poly-ADP-ribose polymerase 1 (PARP1). Objective: This study investigated the correlation between PTEN and PARP1 expression and NACT response in breast carcinomaMethods: Breast carcinoma patients who received NACT in 2017-2018 were consecutively selected, consist of 22 patients with positive NACT response and 22 patients with negative NACT response. Immunohistochemical examination of PTEN and PARP1 was carried out, and their expression was categorized with high and low PTEN expression and high and low PARP1 expression. Statistical analysis using chi-square test was performed to assess the relationship between clinicopathological characteristics, PTEN expression, PARP1 expression, and response to NACT. The significance test was determined at p <0.05.Results: There was a significant relationship between tumor size (p=0.030) and PTEN expression (p=0.035) with the response to NACT in breast carcinoma. Low PTEN expression had a risk of negative clinical response to NACT by 3.754 times compared to breast cancer with high PTEN expression. Meanwhile, there was no significant relationship between PARP1 expression and response to NACT in breast carcinoma.

References

Abdulkareem I, Blair M. Phosphatase and tensin homologue deleted on chromosome 10. Niger Med J. 2013;54(2):79. doi:10.4103/0300-1652.110033

Palma G, Frasci G, Chirico A, et al. Triple negative breast cancer: Looking for the missing link between biology and treatments. Oncotarget. 2015;6(29):26560–26574. doi:10.18632/oncotarget.5306

Carbognin L, Miglietta F, Paris I, Dieci MV. Prognostic and predictive implications of PTEN in breast cancer: Unfulfilled promises but intriguing perspectives. Cancers (Basel). 2019;11(9):1–18. doi:10.3390/cancers11091401

Pascal JM. The comings and goings of PARP-1 in response to DNA damage. DNA Repair (Amst). Published online 2018. doi:10.1016/j.dnarep.2018.08.022

Prasad R, Horton JK, Wilson SH. Requirements for PARP-1 covalent crosslinking to DNA (PARP-1 DPC). DNA Repair (Amst). Published online 2020. doi:10.1016/j.dnarep.2020.102824

Sriwidyani NP, Manuaba IBTW, Alit-Artha IG, Mantik-Astawa IN. Tumor Budding in Breast Carcinoma: Relation to E-Cadherin, MMP-9 Expression, and Metastasis Risk. Bali Med J. 2016;5(3):150. doi:10.15562/bmj.v5i3.335

Beg S, Siraj AK, Prabhakaran S, et al. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer. Breast Cancer Res Treat. 2015;151(3):541–553. doi:10.1007/s10549-015-3430-3

Pierceall WE, Wolfe M, Suschak J, et al. Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic reponse diagnostics. Anal Cell Pathol. 2011;34(3):159–168. doi:10.3233/ACP-2011-014

Rojo F, García-Parra J, Zazo S, et al. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol. 2012;23(5):1156–1164. doi:10.1093/annonc/mdr361

Lu YM, Cheng F, Teng LS. The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review. Sci Rep. 2016;6(August):2–10. doi:10.1038/srep32723

Li S, Shen Y, Wang M, et al. Loss of PTEN expression in breast cancer: Association with clinicopathological characteristics and prognosis. Oncotarget. 2017;8(19):32043–32054. doi:10.18632/oncotarget.16761

Martin HL, Smith L, Tomlinson DC. Multidrug-resistant breast cancer: Current perspectives. Breast Cancer Targets Ther. 2014;6(0):1–13. doi:10.2147/BCTT.S37638

Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8(35):59950–59964. doi:10.18632/oncotarget.19048

Zhang HY, Liang F, Jia ZL, Song ST, Jiang ZF. PTEN mutation, methylation and expression in breast cancer patients. Oncol Lett. 2013;6(1):161–168. doi:10.3892/ol.2013.1331

Chiorean R, Braicu C, Berindan-Neagoe I. Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? Breast. 2013;22(6):1026–1033. doi:10.1016/j.breast.2013.08.007

Kiwerska K, Szyfter K. DNA repair in cancer initiation, progression, and therapy—a double-edged sword. J Appl Genet. 2019;60(3–4):329–334. doi:10.1007/s13353-019-00516-9

Masoud V, Pagès G. Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol. 2017;8(2):120–134. doi:10.5306/wjco.v8.i2.120

Brown JS, O’Carrigan B, Jackson SP, Yap TA. Targeting DNA repair in cancer: Beyond PARP inhibitors. Cancer Discov. 2017;7(1):20–37. doi:10.1158/2159-8290.CD-16-0860

Eldhose E, Gowramma B, Mohammed M, Kalirajan R, Kaviarasan L. Translational Chemotherapy for triple negative Breast Cancer-A Review on significance of poly (ADP-ribose) polymerase 1 (PARP 1) inhibitors. Res J Pharm Technol. 2019;12(6):3098. doi:10.5958/0974-360x.2019.00524.9


Article Views      : 0
PDF Downloads : 0